{"disease":{"id":"giant-cell-arteritis","name":"Giant Cell Arteritis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Giant cell arteritis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Giant Cell Arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"prednisolon","indication_name":"Giant cell arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"triamcinolone","indication_name":"Giant cell arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tocilizumab","indication_name":"Giant cell arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"prednisolone","indication_name":"Giant cell arteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tocilizumab","indication_name":"Giant Cell Arteritis (GCA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."}],"pipeline":[],"offLabel":[],"totalMarketed":27,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06766552","title":"A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT04102930","title":"Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)","phase":"","overall_status":"RECRUITING","enrollment_count":4500,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT02257866","title":"Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","has_results":false},{"nct_id":"NCT05935709","title":"DANIsh VASculitis Database (DANIVAS)","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT07459335","title":"TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1667,"lead_sponsor_name":"Groupe français d'étude des Maladies Inflammatoires de loeil","has_results":false},{"nct_id":"NCT05904301","title":"Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Santé Arménie French-Armenian Research Center","has_results":false},{"nct_id":"NCT06011512","title":"Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Salome Kristensen","has_results":false},{"nct_id":"NCT03410290","title":"Journey of Patients With Vasculitis From First Symptom to Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":456,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03725202","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":429,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07084480","title":"Giant Cell Arteritis - Ways to Precision Medicine","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Wuerzburg University Hospital","has_results":false},{"nct_id":"NCT04930094","title":"Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07246577","title":"The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.","phase":"","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT03658889","title":"Assessment of Giant Cell Arteritis Medical Practices in France","phase":"","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"Chugai Pharma France","has_results":true},{"nct_id":"NCT04885829","title":"Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Syneos Health","has_results":false},{"nct_id":"NCT04664465","title":"PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT01791153","title":"An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05435781","title":"Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Marianne Christina Klose","has_results":false},{"nct_id":"NCT06763783","title":"Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":240,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT07001059","title":"oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound","phase":"NA","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"Hôpital NOVO","has_results":false},{"nct_id":"NCT02703922","title":"Validation of a Diagnostic Algorithm of Giant Cell Arteritis","phase":"NA","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Poitiers University Hospital","has_results":true},{"nct_id":"NCT01588483","title":"Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis","phase":"","overall_status":"COMPLETED","enrollment_count":163,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT02531633","title":"Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":161,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05380453","title":"Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07206238","title":"Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04554290","title":"Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05248906","title":"Giant Cell Arteritis - Optimization of Diagnostics","phase":"","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03409913","title":"Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA","phase":"","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03765424","title":"Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis","phase":"","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06742671","title":"Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Groupe Hospitalier de la Rochelle Ré Aunis","has_results":false},{"nct_id":"NCT06894602","title":"Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT06460142","title":"Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Bonn","has_results":false},{"nct_id":"NCT04519580","title":"Improved Diagnostics and Monitoring of Polymyalgia Rheumatica","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Kresten Krarup Keller","has_results":false},{"nct_id":"NCT05000138","title":"FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis","phase":"","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Jewish General Hospital","has_results":false},{"nct_id":"NCT03600805","title":"Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":83,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT04142515","title":"Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease)","phase":"","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT06271018","title":"TocILizumab in aorTitis in GCA (TILT)","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Groupe français d'étude des Maladies Inflammatoires de loeil","has_results":false},{"nct_id":"NCT07354906","title":"Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Groupe français d'étude des Maladies Inflammatoires de loeil","has_results":false},{"nct_id":"NCT04204512","title":"Comparison of 22Mhz and 18Mhz High-frequency Probes for the Ultrasound Study of Temporal Arteries in Patients Suspected of Having Giant Cell Arteritis","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04049071","title":"TARGET GCAT Registry","phase":"","overall_status":"TERMINATED","enrollment_count":80,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT07108387","title":"Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05246540","title":"Evaluation of PET/CT of Cephalic Arteries for the Diagnosis of Giant Cell Arteritis","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT03827018","title":"KPL-301 for Subjects With Giant Cell Arteritis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Kiniksa Pharmaceuticals, Ltd.","has_results":true},{"nct_id":"NCT04888221","title":"Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06130540","title":"Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02771483","title":"Giant Cell Arteritis and PET Scan (GAPS) Study","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Royal North Shore Hospital","has_results":false},{"nct_id":"NCT06887062","title":"Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT03482479","title":"Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT07508514","title":"Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}